CCCC C4 Therapeutics

C4 Therapeutics to Present at Upcoming Investor Conferences

C4 Therapeutics to Present at Upcoming Investor Conferences

WATERTOWN, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the following upcoming investor conferences:

  • UBS Global Healthcare Conference on Wednesday, May 26, 2021 at 8:00 a.m. ET
  • Jefferies Healthcare Conference on Tuesday, June 1, 2021 at 10:30 a.m. ET

A live webcast of each event can be accessed under “Events & Presentations” in the Investors section of the company’s website at . Replays of the webcasts will be archived on the C4T website for at least two weeks following the applicable presentation date.

About C4 Therapeutics

C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit .



Investor & Media Contact
Kendra Adams
SVP, Communications & Investor Relations
EN
12/05/2021

Underlying

CCCCC4 Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on C4 Therapeutics

 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Rece...

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level Productive Type C Meeting Held With FDA; Registrational Development of Cemsidomide in Multiple Myeloma on Track to Initiate in Early 2026 Preclinical Milestone Achieved Under the Collaboration With Merck KGaA, Darmstadt, Germany, Which ...

August 7, 2025 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recen...

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease Negative Complete Response; 40% ORR Achieved at the 75 µg Dose Level Cemsidomide Multiple Myeloma Dose Escalation is Complete; FDA Feedback Expected by Mid-Year 2025 to Support Initiation of Next Phase of Development in Early 2026 ...

May 7, 2025 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Re...

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million as of December 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Feb. 27, 2025 (GLOBE N...

February 27, 2025 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics to Participate in Upcoming March Investor Conferences

C4 Therapeutics to Participate in Upcoming March Investor Conferences WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences. TD Cowen 45th Annual Healthcare Conference: Management will present on March 3rd at 9:10 am ET in Boston, MA. The live webcast will be available on the of the company’s website. The archived replay of the webcast will be avail...

February 24, 2025 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of...

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma CFT1946 Phase 1 Trial Continues to Progress in BRAF V600X Solid Tumors With Monotherapy Dose Escalation Expected to Complete in 1H 2025; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 CFT8919 Progressing Through Phas...

January 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch